Compounded bioidentical hormones raise concerns

Typically prescribed for perimenopausal and postmenopausal women to manage vasomotor symptoms, cBHT is not regulated or approved by the FDA and therefore is not a recommended treatment option, experts report inViewpoint in JAMA Internal Medicine.Medpage Today
Source: Society for Endocrinology - Category: Endocrinology Source Type: news